bacteri
pneumonia
may
present
primari
diseas
termin
event
individu
alreadi
debilit
secondari
bacteri
infect
result
influenza
infect
caus
half
death
flu
pandem
remain
one
lead
caus
mortal
due
flu
infect
streptococcu
pneumonia
pneumonia
common
pathogen
respons
secondari
bacteri
infect
influenza
pandem
pandem
although
antibiot
wide
use
treatment
secondari
bacteri
infect
detect
fatal
case
mortal
attribut
secondari
pneumonia
infect
valu
increas
patient
intens
care
unit
current
vaccin
pneumonia
pneumococc
conjug
vaccin
reduc
pneumococc
infect
rate
howev
benefit
vaccin
also
significantli
diminish
epidemiolog
shift
among
six
clinic
trial
evalu
vaccin
effect
allcaus
pneumonia
older
adult
one
trial
demonstr
risk
reduct
vaccin
group
find
underscor
import
manag
patient
influenza
may
also
bacteri
pneumonia
although
antibiot
remain
mainstay
treatment
bacteri
pneumonia
broad
usag
limit
may
caus
certain
complic
bacteriolyt
antibiot
treatment
may
erad
pneumonia
caus
releas
cytoplasm
virul
factor
pneumolysin
poreform
toxin
produc
clinic
isol
pneumonia
result
clinic
complic
even
erad
pathogen
lung
infect
free
pneumolysin
caus
disrupt
alveoluscapillari
barrier
lead
pulmonari
leakag
exacerb
diseas
sever
addit
antibiot
resist
recogn
grow
global
threat
resist
new
antibiot
emerg
everincreas
pace
time
rate
develop
new
antibiot
slow
substanti
increas
incid
drugresist
pneumonia
drsp
complic
treatment
manag
variou
pneumococc
diseas
manifest
year
pneumonia
continu
develop
antibiot
resist
pose
seriou
challeng
public
health
particularli
asian
countri
among
highest
rate
antibiot
resist
world
asia
among
isol
belong
promin
serotyp
show
erythromycin
resist
multidrug
resist
respect
clearli
novel
altern
countermeasur
pneumonia
urgent
need
mani
strategi
exploit
compon
immun
system
activ
pursu
although
still
infanc
immunotherapi
antibodi
taken
lead
role
field
view
differ
mode
action
compar
antibiot
antibodi
effect
infect
antibioticresist
pathogen
synergist
use
antibodi
antibiot
effect
approach
manag
difficulttotreat
pneumonia
highthroughput
rna
sequenc
lung
tissu
sampl
patient
influenza
pandem
reveal
angiopoietinlik
protein
one
significantli
upregul
mrna
previous
show
upregul
ctermin
fragment
associ
increas
sever
pulmonari
leakag
damag
primari
influenza
pneumonia
knockout
mice
exhibit
reduc
pulmonari
edema
improv
lung
tissu
integr
primari
influenza
pneumonia
observ
underscor
import
conserv
role
host
respons
infectioninduc
lung
injuri
studi
examin
host
respons
concurr
treatment
secondari
bacteri
pneumonia
neutral
antibodi
togeth
antibiot
andor
bacteri
pneumolysintarget
antibodi
among
clinic
case
influenza
infect
associ
secondari
bacteri
pneumonia
lead
caus
death
pneumonia
common
caus
bacterium
preval
serotyp
encount
asian
popul
wherea
serotyp
virul
address
possibl
role
secondari
pneumococc
pneumonia
develop
sequenti
dualinfect
mous
model
mimick
clinic
scenario
wherein
patient
primari
influenza
infect
suscept
secondari
pneumococc
pneumonia
mice
intratrach
infect
influenza
viru
day
subsequ
infect
intratrach
either
pneumonia
serotyp
day
postinfluenza
infect
dpi
fig
next
examin
host
express
profil
patholog
phenotyp
lung
tissu
sequenti
dualinfect
mous
model
bronchiolar
epithelium
alveolar
tissu
infiltr
immun
cell
damag
influenza
viru
infect
dpi
prior
bacteri
challeng
fig
dpi
lung
harvest
daili
mice
infect
influenza
viru
flu
bacteria
influenza
bacteri
superinfect
assess
extent
edema
infect
lung
volum
harvest
lung
lobe
measur
lung
lobe
edema
display
larger
volum
due
fluid
infiltr
circul
fig
lung
primari
influenzainfect
mice
show
small
signific
increas
lung
volum
primari
bacteri
lung
exhibit
signific
chang
lung
volum
compar
shaminfect
lung
fig
secondari
bacteri
infect
result
significantli
greater
edema
primari
influenza
infect
also
show
clear
pneumococc
serotypespecif
pattern
fig
c
mice
infect
influenza
serotyp
pneumonia
reach
criteria
euthanasia
ie
least
loss
bodi
weight
dpi
fig
lung
mice
infect
display
signific
increas
lung
lobe
volum
compar
shaminfect
lung
fig
pneumonia
cell
detect
pulmonari
epithelium
alveolar
space
determin
fluoresc
situ
hybrid
fish
fluidfil
alveolar
space
may
encourag
bacteri
growth
pneumonia
cell
detect
abund
space
see
fig
supplement
materi
histolog
analysi
lung
reveal
significantli
greater
lung
tissu
damag
secondari
pneumococc
infect
compar
primari
influenza
infect
alon
fig
region
lung
tissu
mice
lost
basic
structur
alveolar
wall
replac
excess
fluid
aris
sever
lung
edema
compar
mice
mice
display
better
preserv
alveolar
structur
although
still
significantli
fluid
infiltr
alveolar
space
compar
mice
influenza
infect
alon
intraalveolar
erythrocyt
immun
cell
infiltr
lung
parenchyma
influenzainfect
mice
primari
bacteri
pneumoniainfect
mice
lung
primari
bacteri
pneumoniainfect
mice
exhibit
pulmonari
tissu
morpholog
similar
healthi
control
lung
suggest
primari
bacteri
infect
caus
notic
tissu
damag
trend
lung
tissu
damag
among
differ
experiment
group
indic
morpholog
alveolar
structur
percentag
intact
alveoli
compar
healthi
lung
lobe
shaminfect
mice
show
uncompromis
alveolar
space
integr
wherea
secondari
pneumococc
pneumoniainfect
mice
suffer
substanti
lung
tissu
injuri
influenzainfect
mice
secondari
pneumococc
pneumoniainfect
mice
reveal
distinct
serotyp
specif
mice
suffer
sever
edema
loss
alveolar
structur
mice
fig
taken
togeth
secondari
pneumococc
infect
follow
primari
influenza
infect
significantli
increas
sever
lung
edema
pulmonari
tissu
damag
serotypespecif
manner
correl
sever
lung
damag
quantit
pcr
qpcr
analysi
show
mrna
level
peak
dpi
lung
infect
flu
compar
shaminfect
lung
fig
immunoblot
analysi
reveal
elev
level
protein
dpi
across
diseas
lung
compar
healthi
lung
fig
immunofluoresc
stain
lung
tissu
reveal
widespread
distribut
mice
primari
influenza
secondari
bacteri
pneumonia
examin
time
point
fig
contrast
primari
bacteri
pneumoniainfect
lung
show
immunostain
pattern
similar
healthi
control
lung
section
restrict
bronchiolar
structur
fig
thu
elev
express
level
correl
well
pulmonari
damag
secondari
bacteri
pneumonia
abund
protein
secondari
bacteri
pneumoniainfect
mous
lung
tissu
suggest
import
role
infectioninduc
pulmonari
damag
end
examin
impact
lung
edema
tissu
integr
secondari
bacteri
pneumonia
use
knockout
mice
fig
b
immunoneutr
fig
mice
secondari
infect
exhibit
less
pulmonari
edema
counterpart
fig
b
indic
arrow
fig
mous
lung
tissu
character
extens
edema
bleed
immun
cell
infiltr
alveolar
space
wherea
mice
infect
show
betterpreserv
integr
alveolar
space
among
mice
mous
lung
tissu
featur
sever
edema
destroy
alveolar
structur
leav
diminish
alveolar
wall
contrast
mice
preserv
alveolar
structur
less
edema
fig
mice
improv
lung
tissu
integr
less
obviou
fig
b
observ
improv
lung
tissu
integr
mice
compar
wildtyp
counterpart
superinfect
indic
higher
percentag
intact
alveolar
space
see
fig
supplement
materi
confirm
result
observ
knockout
mice
explor
therapeut
potenti
treatment
next
studi
effect
defici
caus
inject
monoclon
antibodi
mab
secondari
pneumococc
pneumoniainfect
mice
infect
mice
treat
mab
protect
infectionassoci
lung
damag
better
lung
tissu
integr
reduc
edema
compar
infect
untreat
mice
thu
confirm
find
knockout
experi
fig
indic
higher
percentag
intact
alveolar
space
observ
improv
lung
tissu
integr
mabtreat
mice
compar
control
iggtreat
mice
superinfect
fig
electron
micrograph
confirm
mab
treatment
improv
integr
intercellular
tight
junction
lung
epitheli
cell
compar
igg
control
treatment
fig
panel
iii
contrast
lung
control
iggtreat
mice
show
increas
fibrosi
bacteri
spread
fig
panel
iv
vi
rna
sequenc
analysi
reveal
mab
treatment
improv
immun
function
secondari
bacteri
infect
well
coagul
reduc
bleed
edema
lung
fig
henc
defici
reduc
pulmonari
edema
protect
lung
tissu
integr
suggest
use
therapi
secondari
bacteri
pneumonia
may
benefici
antibiot
constitut
firstlin
therapi
bacteri
pneumonia
complement
current
clinic
practic
secondari
bacteri
pneumoniainfect
mice
treat
mab
moxifloxacin
commonli
use
antibiot
effect
respiratori
infect
combin
treatment
significantli
prolong
median
surviv
time
infect
mice
compar
zero
surviv
mice
receiv
control
igg
treatment
moxifloxacin
alon
fig
see
fig
supplement
materi
moreov
combin
treatment
better
protect
alveolar
integr
reduc
residu
fluid
alveolar
space
thu
indic
efficaci
amelior
lung
edema
diminish
tissu
damag
prolong
surviv
time
fig
fig
c
indic
fig
quantifi
fig
superinfect
destroy
alveolar
structur
caus
sever
edema
lung
infect
wildtyp
mice
antibiot
treatment
alon
protect
alveolar
structur
could
clear
edema
infiltr
immun
cell
although
antipneumolysin
antibodi
treatment
alon
improv
lung
tissu
integr
reduc
edema
improv
signific
observ
use
combin
treatment
antibiot
mab
antipneumolysin
antibodi
fig
fig
efficaci
combin
approach
confirm
mark
improv
mous
surviv
rate
lung
tissu
integr
treatment
group
wildtyp
mice
receiv
antibiot
antipneumolysin
mab
similar
trend
observ
mice
receiv
antibiot
antipneumolysin
treatment
fig
next
perform
transcriptom
analysi
lung
tissu
elucid
detail
host
respons
factor
secondari
pneumococc
pneumonia
variou
treatment
modal
fig
compar
antibiot
treatment
alon
analysi
indic
mab
treatment
combin
antibiot
notabl
improv
immun
respons
bacteri
infect
well
coagul
function
thu
attenu
intraalveolar
hemorrhag
edema
lung
secondari
bacteri
pneumoniainfect
mice
exampl
combin
treatment
yield
increas
activ
coagul
system
pathway
compar
mab
treatment
alon
fig
antibiot
resist
among
clinic
strain
pneumonia
underscor
urgenc
altern
treatment
strategi
multimod
host
pathogendirect
immunotherapi
feasibl
option
thu
employ
experiment
dualinfect
mous
model
explor
concurr
immunotherapi
secondari
bacteri
pneumonia
host
respons
protein
bacteri
virul
factor
pneumolysin
target
use
cognat
neutral
antibodi
antipneumolysin
antibodi
mitig
poreform
action
pneumolysin
human
alveolar
epitheli
cell
reduc
tissu
damag
effect
persist
h
fig
concurr
antibiot
antibodi
treatment
significantli
improv
lung
tissu
integr
importantli
extend
median
surviv
time
mice
secondari
bacteri
pneumonia
compar
treatment
either
antibiot
singl
antibodi
fig
b
taken
togeth
observ
highlight
hostdirect
therapeut
mab
complement
pathogendirect
treatment
convent
antibiot
novel
antipneumolysin
antibodi
enhanc
lung
tissu
integr
augment
host
surviv
secondari
pneumococc
pneumonia
improv
tissu
integr
consider
longer
median
surviv
time
suggest
multimod
treatment
approach
target
host
pathogen
factor
highli
efficaci
drsp
infect
gain
insight
host
respons
secondari
pneumococc
infect
variou
treatment
analyz
immun
cell
gene
express
infect
mous
lung
qpcr
fluorescenceactiv
cell
sorter
fac
sort
major
immun
cell
group
reveal
macrophag
neutrophil
natur
killer
nk
cell
cytotox
cell
b
cell
express
variou
level
secondari
pneumococc
pneumonia
fig
mous
lung
semidigest
bacteria
appear
within
lymphocyt
cytoplasm
antibodymedi
neutral
augment
abil
macrophag
phagocytos
fulli
digest
bacteria
fig
improv
phagocytosi
bacteri
digest
suggest
treatment
enhanc
host
immun
function
next
interrog
transcriptom
lung
tissu
understand
detail
host
respons
factor
secondari
pneumococc
infect
variou
treatment
analysi
show
antibodi
treatment
either
alon
combin
antibiot
treatment
increas
express
host
immun
defenserel
gene
code
tolllik
receptor
tumor
necrosi
factor
tnf
gamma
interferon
decreas
express
antiinflammatori
gene
fig
interestingli
combin
treatment
use
antibiot
gener
greater
enhanc
gene
express
treatment
alon
wherea
antibiot
treatment
alon
produc
opposit
effect
term
regul
gene
fig
given
insuffici
host
immun
respons
major
contributori
factor
lethal
outcom
secondari
bacteri
pneumonia
appar
posit
effect
therapi
immun
respons
could
consid
benefici
host
defens
bacteri
infect
consist
improv
phagocytosi
bacteri
digest
fig
clinic
isol
pneumonia
secret
toxic
poreform
pneumolysin
support
potenti
broad
applic
antipneumolysin
antibodi
new
treatment
drsp
infect
similarli
underscor
potenti
use
therapi
pulmonari
diseas
examin
protein
level
bronchoalveolar
lavag
fluid
balf
patient
acut
respiratori
distress
syndrom
ard
n
compar
healthi
volunt
control
n
ard
balf
sampl
show
significantli
higher
protein
level
detect
immunoblot
fig
howev
mark
increas
observ
serum
sampl
pneumonia
patient
n
compar
nonpneumonia
patient
control
n
fig
find
indic
protein
elev
pulmonari
fluid
patient
sever
pneumonia
wherea
level
blood
circul
may
influenc
factor
also
support
potenti
util
biomark
therapeut
target
diagnosi
treatment
infectionassoci
lung
injuri
pneumonia
major
caus
acut
pneumonia
commonli
identifi
pathogen
secondari
bacteri
lung
infect
increas
preval
multidrugresist
pneumonia
also
pose
seriou
public
health
concern
worldwid
particularli
asian
countri
secondari
bacteri
pneumonia
present
uniqu
set
host
respons
challeng
rapidli
progress
infect
often
poor
prognosi
newer
approach
improv
treatment
outcom
need
reduc
high
morbid
mortal
studi
examin
effect
antibodybas
immunotherapi
secondari
pneumococc
pneumonia
studi
multimod
treatment
concurr
target
host
pathogen
factor
experiment
mous
model
secondari
pneumonia
infect
shown
significantli
improv
lung
tissu
integr
extend
median
surviv
time
infect
mice
immunoneutr
host
protein
significantli
diminish
sever
pulmonari
edema
damag
combin
pathogendirect
therapi
antibiot
antipneumolysin
mab
attenu
bacteri
replic
toxic
ultim
consider
prolong
surviv
infect
mice
effect
antibodi
treatment
secondari
bacteri
infect
also
confirm
use
mice
complic
death
aris
influenza
secondari
pneumonia
often
associ
hyperinduct
proinflammatori
cytokin
chemokin
phenomenon
also
known
cytokin
storm
hypercytokinemia
patient
die
ard
common
consequ
hypercytokinemia
infect
per
se
pathogeninduc
lung
injuri
manifest
mild
sever
ard
seen
sever
acut
respiratori
syndrom
sar
coronaviru
influenza
viru
secondari
bacteri
pneumococc
infect
although
inflammatori
process
constitut
import
treatment
target
antiinflammatori
treatment
inhibit
immun
function
mediat
pathogen
clearanc
compromis
host
immun
respons
influenza
infect
render
host
vulner
secondari
bacteri
infect
particularli
crucial
sinc
secondari
bacteri
infect
usual
facilit
influenza
viru
impair
host
immun
respons
alter
cytokin
product
thu
favor
bacteri
superinfect
greatli
increas
host
morbid
mortal
exampl
treatment
target
proinflammatori
cytokin
reactiv
oxygen
speci
ro
reactiv
nitrogen
speci
rn
come
risk
enhanc
pathogen
replic
ideal
potenti
treatment
regimen
minim
tissu
damag
caus
inflamm
facilit
recoveri
without
interf
host
antivir
antibacteri
respons
host
bacteri
factor
contribut
sever
tissu
damag
pneumonia
thu
offer
critic
target
therapi
develop
therapeut
use
passiv
antibodi
well
establish
sever
primari
viral
infect
similarli
passiv
immun
afford
antibodi
pathogen
virul
factor
pneumolysin
enhanc
surviv
rate
mice
primari
bacteri
pneumonia
pneumolysin
gene
limit
variabl
therefor
prime
pathogen
target
antipneumolysin
mab
target
oligomer
domain
conserv
across
strainspecif
unlik
previous
report
antipneumolysin
antibodi
recent
insight
pathogenhost
interact
host
innat
immun
respons
also
led
identif
develop
wide
rang
hostdirect
therapi
differ
mechan
action
one
approach
target
vascular
leakag
combat
respiratori
diseas
recent
studi
identifi
key
player
tissu
leaki
primari
influenza
pneumonia
lipopolysaccharideinduc
acut
lung
injuri
associ
increas
express
influenzainfect
mice
exhibit
reduc
lung
tissu
leaki
damag
compar
mice
function
similarli
suppress
small
interf
rna
sirna
also
protect
mice
lipopolysaccharideinduc
acut
lung
injuri
inde
compar
individu
therapi
concurr
treatment
mab
moxifloxacin
consider
extend
surviv
mice
secondari
bacteri
pneumonia
due
differ
mode
action
compar
antibiot
immunotherapi
antibodi
highli
effect
secondari
drsp
infect
caus
antibioticresist
pathogen
coimmunoneutr
pneumolysin
effect
secondari
bacteri
pneumonia
culmin
improv
pulmonari
function
longer
surviv
time
taken
togeth
studi
highlight
hostdirect
therapeut
strategi
valuabl
adjunct
complement
enhanc
standard
antimicrobi
treatment
influenza
viru
apuerto
strain
obtain
american
type
cultur
collect
propag
embryon
egg
viral
titer
determin
plaqu
assay
serotyp
pneumonia
deriv
clinic
isol
singapor
cultur
brain
heart
infus
broth
sigma
supplement
heatinactiv
fetal
bovin
serum
fb
anaerob
condit
midlogarithm
phase
femal
balbc
mice
week
old
purchas
invivo
singapor
kept
biosafeti
level
anim
facil
nanyang
technolog
univers
singapor
anim
experi
approv
institut
anim
care
use
committe
iacuc
nanyang
technolog
univers
singapor
nation
univers
singapor
mice
anesthet
use
mgkg
bodi
weight
ketamin
mgkg
bodi
weight
xylazin
infect
via
intratrach
deliveri
viru
subleth
dose
pfu
phosphatebuff
salin
pb
day
postinfluenza
infect
cfu
serotyp
cfu
serotyp
pneumonia
pb
deliv
intratrach
mice
sham
infect
perform
use
steril
pb
immedi
bacteri
infect
mice
inject
intraperiton
moxifloxacin
mgkg
bodi
weight
antibodi
mgkg
bodi
weight
antipneumolysin
antibodi
mgkg
bodi
weight
control
igg
mgkg
bodi
weight
daili
start
day
postinfluenza
infect
harvest
mice
euthan
specifi
time
point
lung
tissu
harvest
lung
lobe
either
fix
paraformaldehyd
histolog
analysi
snapfrozen
liquid
nitrogen
kept
subsequ
assay
antimous
antibodi
antihuman
antibodi
produc
inhous
describ
previous
antipneumolysin
antibodi
prepar
cultur
hybridoma
cultur
dulbecco
modifi
eagl
medium
dmem
fb
purifi
cultur
medium
use
igg
purif
kit
merck
millipor
antibodi
purchas
abcam
fix
mous
lung
dehydr
embed
paraffin
fivemicromet
section
mount
slide
coat
superfrost
plu
thermal
scientif
section
dewax
xylen
rehydr
water
immunofluoresc
stain
perform
previous
describ
section
mount
antifad
reagent
contain
dapi
invitrogen
imag
captur
observ
fluoresc
microscop
carl
zeiss
hematoxylin
eosin
h
e
stain
perform
histopatholog
analysi
lung
tissu
pneumonia
lung
section
detect
employ
fluoresc
situ
hybrid
fish
describ
minor
modif
briefli
follow
dehydr
fix
lung
section
ethanol
seri
min
ethanol
overnight
hybrid
rrna
pneumonia
perform
spn
probe
tag
hybrid
buffer
contain
formamid
wash
step
section
mount
antifad
reagent
imag
use
invert
confoc
laserscan
microscop
carl
zeiss
fit
plan
apochromat
oil
len
object
excit
nm
autofluoresc
nm
microscop
imag
process
use
imari
softwar
version
pneumonia
pseudocolor
green
immun
cell
harvest
influenza
viru
pneumonia
serotyp
mice
day
postinfluenza
viru
infect
bronchoalveolar
lavag
one
millilit
steril
pb
inject
mous
lung
trachea
retriev
syring
balf
contain
immun
cell
damag
lung
tissu
cell
pellet
centrifug
g
min
stain
flow
cytometri
sort
use
bd
facsaria
follow
surfac
marker
use
macrophag
isothiocyan
fitc
pe
neutrophil
natur
killer
cell
cytotox
cell
tc
apc
thelper
cell
th
b
cell
unstain
cell
serv
neg
control
antibodi
cell
sort
biolegend
sort
cell
use
rna
extract
quantit
realtim
revers
transcriptionpcr
rtpcr
total
rna
extract
revers
transcrib
previous
describ
pcr
perform
biorad
realtim
system
use
kapa
sybr
fast
qpcr
master
mix
accord
manufactur
instruct
kapa
biosystem
primer
use
mous
forward
revers
housekeep
primer
forward
revers
lung
tissu
lyse
mper
mammalian
extract
buffer
pierc
protein
concentr
determin
use
biorad
protein
assay
kit
protein
sampl
heat
laemmli
sampl
buffer
resolv
sdspage
transfer
lowfluoresc
polyvinyliden
difluorid
pvdf
membran
millipor
immunoblot
perform
previous
describ
total
rna
extract
frozen
mous
lung
tissu
use
trizol
thermo
fisher
integr
total
rna
level
dna
contamin
assess
agil
bioanalyz
agil
technolog
qubit
fluoromet
invitrogen
librari
prepar
perform
accord
mrnaseq
sampl
prepar
kit
illumina
sequenc
use
illumina
miseq
platform
singleend
sequenc
sequenc
read
map
onto
viral
pneumonia
mous
genom
use
clc
genom
workbench
differenti
gene
express
determin
use
r
statist
packag
follow
criteria
adopt
filter
uniqu
sequenc
read
maximum
number
hit
read
minimum
length
fraction
minimum
similar
fraction
maximum
number
two
mismatch
constant
ad
raw
transcript
count
valu
avoid
problem
caus
packag
rbioconductor
use
statist
analysi
transcript
count
tabl
transcript
count
normal
effect
librari
size
differenti
express
gene
identifi
perform
neg
binomi
test
transcript
determin
differenti
express
show
chang
adjust
p
valu
pathway
analysi
data
present
perform
use
ingenu
pathway
analysi
softwar
qiagen
bioinformat
balf
sampl
obtain
pneumonia
patient
fulfil
ard
diagnost
criteria
american
european
consensu
confer
control
balf
sampl
obtain
healthi
volunt
balf
collect
three
instil
steril
physiolog
salin
ml
flexibl
bronchoscop
previous
describ
collect
lavag
fluid
pass
two
sheet
gauz
centrifug
g
min
supernat
store
use
studi
protocol
approv
institut
review
board
nagasaki
univers
hospit
japan
serum
sampl
obtain
patient
diagnos
pneumonia
success
treatment
antibiot
biolog
resourc
center
ferdinand
cabann
dijon
centr
hospitali
universitair
de
dijon
franc
inform
consent
obtain
subject
experi
conform
principl
outlin
wma
declar
helsinki
depart
health
human
servic
belmont
report
statist
analysi
perform
unpair
test
use
graphpad
prism
version
graphpad
softwar
valu
depict
mean
standard
error
mean
sem
p
valu
consid
statist
signific
rna
sequenc
data
submit
ncbi
bioproject
databas
bioproject
sra
access
